Celgene Revenue

Celgene revenue was $15.28 b in FY, 2018 which is a 17.5% year over year increase from the previous period.

Embed Graph

Summary - Funding Rounds

Founding Date

1986
Celgene is a subsidiary of Bristol-Myers Squibb

Celgene Revenue Breakdown

Embed Graph

Celgene revenue breakdown by business segment: 89.4% from Hematology / Oncology, 10.5% from Inflammation & Immunology and 0.1% from Other

Celgene revenue breakdown by geographic segment: 34.4% from International and 65.6% from U.S.

Celgene Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018

Revenue

11.2b13.0b15.3b

Revenue growth, %

21%16%18%

Cost of goods sold

438.0m461.0m587.0m

Gross profit

10.8b12.5b14.7b

Gross profit Margin, %

96%96%96%

R&D expense

4.5b5.9b5.7b

General and administrative expense

2.7b2.9b3.3b

Operating expense total

7.6b7.8b9.5b

Depreciation and amortization

459.0m329.0m468.0m

EBIT

3.2b4.7b5.2b

EBIT margin, %

28%36%34%

Interest expense

500.1m522.0m741.0m

Pre tax profit

2.4b4.3b4.8b

Income tax expense

373.3m1.4b786.0m

Net Income

2.0b2.9b4.0b

EPS

2.53.65.5

Celgene Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018

Cash

6.2b7.0b4.2b

Accounts Receivable

1.6b1.9b2.1b

Inventories

497.9m541.0m458.0m

Current Assets

10.9b14.9b9.1b

PP&E

929.8m1.1b1.4b

Goodwill

4.9b4.9b8.0b

Total Assets

28.1b30.1b35.5b

Accounts Payable

247.1m305.0m418.0m

Short-term debt

500.7m501.0m

Current Liabilities

3.0b3.0b4.1b

Long-term debt

137.9b15.8b19.8b

Total Debt

138.4b15.8b20.3b

Total Liabilities

21.5b23.2b29.3b

Common Stock

9.5m10.0m10.0m

Preferred Stock

Additional Paid-in Capital

12.4b13.8b15.0b

Retained Earnings

10.1b13.1b17.6b

Total Equity

6.6b6.9b6.2b

Debt to Equity Ratio

21 x2.3 x3.3 x

Debt to Assets Ratio

4.9 x0.5 x0.6 x

Financial Leverage

4.3 x4.4 x5.8 x

Celgene Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018

Net Income

2.0b2.9b4.0b

Depreciation and Amortization

504.7m471.0m635.0m

Accounts Receivable

(222.4m)(236.0m)(178.0m)

Inventories

(55.3m)(42.0m)82.0m

Accounts Payable

618.9m273.0m290.0m

Cash From Operating Activities

4.0b5.2b5.2b

Purchases of PP&E

(236.2m)(279.0m)(330.0m)

Cash From Investing Activities

(1.0b)(2.9b)(6.4b)

Short-term Borrowings

(100.3m)(5.7b)

Long-term Borrowings

(1.9b)

Cash From Financing Activities

(1.6b)(1.6b)(1.5b)

Net Change in Cash

1.3b843.0m(2.8b)

Interest Paid

527.2m539.0m689.0m

Income Taxes Paid

373.0m475.0m1.2b

Celgene Ratios

USDFY, 2016

Revenue/Employee

1.6m

Debt/Equity

21 x

Debt/Assets

4.9 x

Financial Leverage

4.3 x

Celgene Operating Metrics

FY, 2016FY, 2017FY, 2018

Active Clinical Studies

52

Filed Trials Products (Acute Myeloid Leukemia)

233

Filed Trials Products (Inflammation and Immunology)

222

Filed Trials Products (Lymphoma)

466

Filed Trials Products (Multiple Myeloma)

455

Filed Trials Products (Myelodysplastic Syndromes)

222

Filed Trials Products (Solid Tumors)

444

Phase I Trials Products (Acute Myeloid Leukemia)

323

Phase I Trials Products (Cellular Therapies)

2

Phase I Trials Products (Chronic Lymphocytic Leukemia)

21

Phase I Trials Products (Inflammation and Immunology)

333

Phase I Trials Products (Lymphoma)

555

Phase I Trials Products (Multiple Myeloma)

644

Phase I Trials Products (Myelodysplastic Syndromes)

11

Phase I Trials Products (Solid Tumors)

453

Phase I/II Trials Products (Chronic Lymphocytic Leukemia)

11

Phase I/II Trials Products (Lymphoma)

11

Phase I/II Trials Products (Multiple Myeloma)

1

Phase II Trials Products (Acute Myeloid Leukemia)

11

Phase II Trials Products (Cellular Therapies)

2

Phase II Trials Products (Inflammation and Immunology)

663

Phase II Trials Products (Multiple Myeloma)

11

Phase II Trials Products (Myelodysplastic Syndromes)

221

Phase II Trials Products (Myelofibrosis)

11

Phase II Trials Products (Solid Tumors)

33

Phase III Trials Products (Acute Myeloid Leukemia)

111

Phase III Trials Products (Beta Thalassemia)

111

Phase III Trials Products (Inflammation and Immunology)

524

Phase III Trials Products (Lymphoma)

433

Phase III Trials Products (Myelodysplastic Syndromes)

222

Phase III Trials Products (Solid Tumors)

114

Celgene Sustainability Metrics

 FY, 2018

Water Withdrawn

502.58 k cubic meters

Total Injury Rate

0.44

Lost Day Rate

0.11

Greenhouse Gas Emissions (Scope 3, Waste)

1.33 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Other)

2.14 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Employee Commuting)

21.7 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Business Travel)

13.57 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3)

38.74 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 2)

10.48 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1)

24.02 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1 and Scope 2)

34.5 k metric tons of carbon dioxide equivalent

Energy Purchased (Renewable Electricity)

78.81 k MWh

Energy Consumption

828.59 k GJ

Celgene Human Capital

Celgene's employees are reported to be approximately 52% female and 48% male.
FY, 2018FY, 2017FY, 2016
Male47.5%47.2%31.7%
Female52.5%52.8%36.6%

Celgene Employee Rating

4546 votes
Culture & Values
3.9
Work/Life Balance
3.8
Senior Management
3.3
Salary & Benefits
4.1
Career Opportunities
3.5
Source